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(57) ABSTRACT 
A novel system and method for fluid management for accu-
rate continuous venovenous hemofiltration (CWH) in extra-
corporeal membrane oxygenation (ECMO). The fluid man-
agement or CWH system is automated and configured for 
operation as a stand alone unit and can be easily integrated 
with an ECMO system. The fluid management system is 
capable of producing either perfect or negative fluid balance 
between ultrafiltrate removal and replacement fluid delivery. 
The fluid management system can achieve electrolyte 
replacement over a range of flow rates needed to care for 
patients ranging from neonates to adults. Finally, the novel 
fluid management system preserves patient safety, maintains 
sterility during operation, is easy to operate, and is compact 
enough to fit near a patient's bed. 
18 Claims, 14 Drawing Sheets 
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FLUID MANAGEMENT SYSTEM FOR 
ACCURATE CONTINUOUS 
HEMOFILTRATION IN EXTRACORPOREAL 
MEMBRANE OXYGENATION (ECMO) 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
2 
diuretics, which has been suggested to worsen outcomes in 
critically ill adults with renal failure. 
Renal support can be provided by a continuous renal 
replacement therapy (CRRT) such as continuous venovenous 
hemofiltration (CVVH). This technique allows for precise 
control of fluid balance by providing continuous fluid, elec-
trolyte and toxin clearance even in the absence of adequate 
native renal function via convective processes through a per-
meable membrane. The hemofiltration retains proteins and This application is a National Stage Application of PCT/ 
US2008/066108, filed 6 Jun. 2008, in the name of Georgia 
Tech Research Corporation, a U.S. national corporation, 
applicant for all countries except the US, and Philippe 
Sucosky, a citizen of France, Lakshmi Prasad Dasi, a citizen 
of India, and Ajit P. Yoganathan, James D. Fortenberry, and 
Matthew L. Paden, all citizens of the U.S., applicants for the 
designation of the US only, and which claims benefit of 
United States provisional patent application Ser. No. 601942, 
218 filed Jun. 6, 2007, and which applications are incorpo-
rated herein by reference. To the extent appropriate, a claim of 
priority is made to each of the above disclosed applications. 
10 cellular components of the intravascular space and eliminates 
plasma water and dissolved solutes. A typical CVVH setup 
consists of a hemofilter and a pair of pumps to achieve the 
drainage of the ultrafiltrate which is discarded and the deliv-
ery of replacement fluid, respectively. The portion of the 
15 ultrafiltrate that corresponds to body weight loss within a 
patient is discarded merely as removal filtrate. However, 
when the excess of the ultrafiltrate other than the removal 
filtrate is discarded, blood that has been filtered must be given 
a replacement fluid in an amount equal to the amount of the 
FIELD OF INVENTION 
20 excess to maintain the water balance of the patient. It is 
known that most optimally the living body should be given 
replacement fluid continuously at the same rate as the dis-
charge of the excess of ultrafiltrate. To meet these require-
ments, it is critical for CVVH systems to measure the 
The present invention relates to systems and methods for 
fluid management in critically ill patients. More particularly, 
the present invention relates to systems and methods for fluid 
management that is continuous, automated, and accurate for 
treatment of critically ill patients who also require extracor-
poreal membrane oxygenation treatment. 
25 amounts of the ultrafiltrate, excess ultrafiltrate and replace-
ment fluid. 
To supply the replacement fluid continuously in balance 
with the excess ultrafiltrate, systems have been proposed 
which include those of the type in which the volume of 
BACKGROUND OF THE INVENTION 
30 ultrafiltrate removed is determined by indirect measurements 
such as rate ofremoval ofultrafiltrate or weight of the ultra-
filtrate removed. Such systems inherently are inaccurate 
because they are using surrogates to determine volume. In 
such systems, there shall always be an error within the volume Extracorporeal life support (ECLS) is a widely used tech-
nique in intensive care units to assist patients with severe 
organ deficiencies. Among the different ECLS techniques, 
extracorporeal membrane oxygenation (ECMO) provides 
life-saving temporary heart and lung support to patients who 
experience cardiac and/or respiratory failure unresponsive to 
standard ventilator and pharmacologic management. The 
clinical implementation ofECMO varies, but generally con-
sists of a drain cannula through which blood is drained from 
the patient's venous system, a roller or centrifugal pump, a 
membrane oxygenator that oxygenates the blood and 
removes carbon dioxide, a bladder pressure module, a heat 45 
exchanger, and an arterial cannula through which the oxygen-
ated blood is returned to the patient's arterial system. 
35 determination because the measurements are not directly on 
volume itself. The error that occurs may be small and insig-
nificant when treating patients of an adult size. However, 
when these errors are scaled down and the patient is a 3 
kilogram infant, the errors become significant, causing the 
40 patient to be thermodynamically unstable 
Although the implementation of ECMO in the neonatal, 
pediatric and adult intensive care unit has been shown to 
result in improved survival rates, it is also associated with 50 
some complications. Patients treated with ECMO may expe-
rience acute renal failure due to combined renal hypoperfu-
sion and hypoxemia as a result of their primary disease, 
resulting ultimately to a decreased urine output. Since ill-
nesses leading to cardio respiratory failure can require large 55 
volumes of fluid resuscitation, patients often received large 
amounts of crystalloid and blood products during their pre-
ECMO course and may develop serious fluid overload. This 
fluid overload is associated with pulmonary edema, worsen-
ing lung injury, and increased incidence of multiple organ 60 
failure in critically ill patients. Recent studies have suggested 
that improved fluid balance could be associated with 
improved outcomes in critically ill patients. Fluid restriction 
can be employed in management; however this is often at the 
expense of decreasing caloric intake, which could be detri- 65 
mental to improving overall outcomes. Treating or preventing 
fluid overload in this setting can require aggressive use of 
CVVH has also been used in combination with other extra-
corporeal therapies, including ECM 0. In that configuration, a 
single roller pump drives simultaneously the blood in the 
ECMO and CVVH circuits. Blood from the oxygenator is 
drained to the hemofilter and returns to the ECMO circuit via 
the ECMO bladder. A recent study reported that percent fluid 
overload was correlated with mortality in patients receiving 
CVVH. In another case report, the benefits of a combined 
ECMO-CVVH therapy were assessed to treat neonatal car-
diac and respiratory failure. The results demonstrated that the 
reduction of fluid overload via CVVH could lead to a signifi-
cant improvement in both oxygenation and cardiac output. 
Finally, similar benefits were observed when implementing 
CVVH along with ECMO in the pediatric intensive care unit. 
Those results suggest that the use of CVVH during ECMO is 
associated with improved fluid balance and caloric intake 
with less use of diuretics compared to standard ECMO 
approaches. 
Significant issues associated with the implementation of 
this combined therapy are the complexity, cost, staffing 
requirements, and increased risk to an already complicated 
and expensive ECMO course of action. Although devices 
such as the Diapact (B. Braun Medical Inc., Bethlehem, Pa.) 
and the Prisma (Gambro Dasco S.p. A., Medolla, Italy) are 
commercially available and use a weight-based method of 
ensuring accuracy, no commercially available CRRT device 
is specifically approved for use in conjunction with ECMO. 
US 8,206,594 B2 
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Additionally, the Diapact's use is limited in neonatal and 
pediatric patients because the lowest ultrafiltration rate is 300 
ml/hour and many patients in pediatric care require less than 
that. There is a need for a simplified ECMO-CVVH setup 
which may solve these and the many other potential problems 
associated with current ECMO-CVVH systems. 
4 
therapy across the range of size and weight seen from infancy 
to adulthood. There exists a need for systems and methods for 
fluid management capable of producing either perfect or 
negative fluid balance between ultrafiltrate removal and 
replacement fluid delivery. There also exists a need for sys-
tems and methods for fluid management capable of achieving 
electrolyte replacement over a range of flow rates needed to 
care for patients ranging from neonates to adults. Finally, 
there exists a need for systems and methods for fluid man-
10 agement that preserves patient safety, maintains sterility, is 
easy to operate, and is compact enough to fit near a patient's 
bed. 
When using ECMO-CCVH systems, close attention is 
required to assess patient level of hydration as some inaccu-
racy in pump delivery of replacement fluid volume and pump 
extraction ofultrafiltrate fluid volume can occur, creating the 
potential for excessive fluid removal. Clinical experience has 
suggested that significant differences between set and 
observed fluid removal rates can occur, leading to cases of 
dehydration out of proportion to desired rates. Preliminary 
observations suggested that this difference might be due to 15 
replacement fluid pump inaccuracy of up to 12.5%. This 
inaccuracy has discouraged some ECMO physicians from 
using this potentially beneficial technique due to the lack of a 
simple and accurate intravenous fluid pump system capable 
of working against high flow rates seen in patients on ECMO. 20 
There is a need for an ECMO-CVVH system that also solves 
these problems. 
Many patients not receiving ECMO also require renal 
replacement therapy in the intensive care unit while they are 
ill. CVVH is a common method of providing renal replace- 25 
ment therapy to critically ill and hemodynamically unstable 
patients in the pediatric intensive care unit. There is currently 
no FDA approved CVVH device for use in the neonatal and 
pediatric populations. Currently, because there is no other 
available choice approved for pediatrics and the fact that 30 
untreated renal failure can lead to death, physicians may 
resort to utilizing CVVH devices approved for adults to treat 
children. However, when adult approved CVVH devices are 
used on smaller patients, similar inaccuracy in fluid manage-
ment as described above occur and complications are com- 35 
mon. 
SUMMARY OF THE INVENTION 
The present invention is an accurate continuous veno-
venous hemofiltration (CVVH) fluid management system 
that is configured for operation as a stand alone unit and for 
integration with an ECMO circuit. It is an objective of the 
CVVH system to produce either a zero or negative fluid 
balance between the replacement fluid delivered to the patient 
and the ultrafiltrate extracted from the hemofilter. The present 
invention also discloses a method for managing fluid for 
accurate continuous venovenous hemofiltration, comprising 
the steps of filling a first container with replacement fluid; 
continuously filtering unfiltered blood to extract ultrafiltrate; 
transferring the replacement fluid from the first container to 
the filtered blood; occurring simultaneously with the perfor-
mance of the previous step, transferring the ultrafiltrate to a 
second container in an amount equal to the amount of replace-
ment fluid transferred from the first container; continuously 
monitoring the state of replacement fluid in the first container 
and the state of ultrafiltrate in the second container; upon 
detecting that the first container no longer contains replace-
ment fluid, stopping the transfer ofultrafiltrate to the second 
container; after transferring all of the replacement fluid from 
the first container, refilling the first container with additional 
replacement fluid; and occurring simultaneously with the 
performance of the previous step, emptying the ultrafiltrate 
There exists a need for systems and methods for fluid 
management for accurate continuous venovenous hemofiltra-
tion, which in some instances is combined and integrated with 
extracorporeal membrane oxygenation. In prior art systems in 
which a fluid management system is integrated with an 
ECMO system, as illustrated in FIG. 1, blood is filtered via a 
hemofilter 120 and the ultrafiltrate 125 is extracted from the 
hemofilter 120 via a first pump 130. Simultaneously, a second 
pump 135 delivers some replacement fluid 140 back into the 
filtered blood within the bladder 105. The main disadvantage 
40 that is in the second container so that the second container no 
longer contains ultrafiltrate. 
A method of the present invention further comprises the 
step of repeating the foregoing steps to achieve a zero fluid 
balance between the ultrafiltrate extracted from the filtered 
45 blood and the replacement fluid transferred to the filtered 
blood. 
of the combined system illustrated in FIG. 1 is the large 
pressure under which the ECMO circuit operates. The use of 
IV pumps 130, 135 to deliver or extract high flow rates of 
fluids under a pressure much higher than in the human body is 50 
controversial. The accuracy of a typical IV pump was tested in 
terms of the error between the progranimed flow rate and the 
actual flow rate delivered by the pump for a range of pressures 
between 120 and 180 mmHg. The experiments that were 
repeated at three different flow rates (i.e., 1 L/hour, 500 55 
mL/hour and 300 mL/hour) revealed an error increasing as a 
function of pressure and as a function of flow rate, illustrated 
in FIG. 2. Therefore, operating the two IV pumps of the 
CVVH circuit under the typical pressure of the ECMO circuit 
could lead to an increased ultrafiltrate removal from the 60 
To achieve a negative fluid balance between the ultrafiltrate 
extracted from the filtered blood and the replacement fluid 
transferred to the filtered blood, the method of the present 
invention further comprises the steps of transferring a portion 
of the replacement fluid to a third container so that the portion 
of replacement fluid transferred to the third container is not 
combined with the filtered blood and emptying the portion of 
the replacement fluid that is in the third container so that the 
third container no longer contains replacement fluid. 
In addition, a method of the present invention may also 
comprise the step of continuously monitoring a patient to 
determine the need for zero fluid balance and negative fluid 
balance. 
The present invention also discloses a system for managing 
fluid for accurate continuous venovenous hemofiltration, 
comprising a hemofilter continuously filtering unfiltered 
blood to extract ultrafiltrate; a first container filled with 
replacement fluid, wherein the replacement fluid is trans-
patient and decreased fluid replacement to the patient. This 
phenomenon that has been observed to be more significant in 
smaller patients could result in rapid dehydration and could 
ultimately lead to shock. There is a need for a combined 
CVVH and ECMO system that solves this problem. 
There also exists a need for a stand alone CVVH system 
designed specifically to provide accurate fluid management 
65 ferred from the container to the filtered blood; a second con-
tainer and the first container coupled to a translating arm, 
wherein the translating arm moves to simultaneously allow 
US 8,206,594 B2 
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the replacement fluid to be transferred from the first container 
to the filtered blood and allow the ultrafiltrate to be transferred 
from the hemofilter to the second container, the amount of the 
replacement fluid and the ultrafiltrate transferred being equal 
to each other; at least one sensor being structurally connected 
6 
FIGS. 9A and 9B are drawings showing the mechanisms 
involved in the production of a negative fluid balance accord-
ing to the present invention; and 
FIG. 10 is a schematic representation of stand alone CVVH 
system of the present invention. 
to the translating arm to continuously monitor the relative 
position of the translating arm, thereby determining whether 
there is replacement fluid contained in the first container and 
ultrafiltrate contained in the second container; upon at least 
one sensor detecting that the translating arm is in a minimum 10 
or a maximum position in connection with the first container 
and the second container, means for causing the translating 
arm to stop and reverse its direction, wherein, in a first phase, 
the first container is refilled with additional replacement fluid 
15 
at the same time as the ultrafiltrate is emptied from the second 
container, or wherein, in a second phase, the replacement 
fluid is transferred from the first container at the same time as 
the ultrafiltrate is extracted from the hemofilter and trans-
DETAILED DESCRIPTION OF A PREFERRED 
EMBODIMENT 
Various embodiments are described more fully below with 
reference to the accompanying drawings, which form a part 
hereof, and which show specific embodiments of the inven-
tion. However, embodiments may be implemented in many 
different forms and should not be construed as limited to the 
embodiments set forth herein; rather, these embodiments are 
provided so that this disclosure will be thorough and com-
plete, and will fully convey the scope of the invention to those 
skilled in the art. Accordingly, the following detailed descrip-
tion is, therefore, not to be taken in a limiting sense. 
ferred to the second container. The foregoing system allows 20 
one to achieve a zero fluid balance between the ultrafiltrate 
extracted from the filtered blood and the replacement fluid 
transferred to the filtered blood. 
Referring now to FIG. 3A, the present invention is a com-
bined ECMO-CVVH system 300 comprised of an ECMO 
bladder 30S, a blood pump 310, an oxygenator 3 lS, and a flow 
probe 32S. Blood is continuously drained from a patient's 
venous system and circulated through the ECMO bladder The present invention discloses a system further compris-
ing a third container for containing a portion of the replace-
ment fluid that is being transferred from the first container to 
the filtered blood so that the portion of replacement fluid 
transferred to the third container is not combined with the 
filtered blood, thereby producing a negative fluid balance 
between the ultrafiltrate extracted from the filtered blood and 
the replacement fluid transferred to the filtered blood. 
The aforementioned system achieves a perfect fluid bal-
ance. However, to achieve a net negative fluid balance, a 
singular piston-syringe is needed. This piston-syringe is con-
nected to the replacement fluid piston-syringe to extract a 
portion of the replacement fluid to achieve a net negative fluid 
balance. 
BRIEF DESCRIPTION OF THE DRAWINGS 
Non-limiting and non-exhaustive embodiments are 
described with reference to the following figures, wherein 
like reference numerals refer to like parts throughout the 
various views unless otherwise specified. 
FIG. 1 is a schematic representation of a prior art ECMO-
CVVH system; 
FIG. 2 is a graphical representation of IV pump accuracy 
measurements, namely showing flow rate error as a function 
of pressure differential applied across an IV pump; 
FIGS. 3A and 3B are schematic representations ofECMO-
CVVH systems of the present invention; 
FIGS. 4A and 4B are drawings depicting the principles of 
conservation of volume in fluid management as applied 
according to the present invention; 
FIGS. SA and SB are drawings showing the front and back 
views, respectively, of a novel CVVH or fluid management 
device; 
25 30S. The blood pump 310 draws blood from the ECMO 
bladder 30S, which works like the right atrium. The function 
of this ECMO bladder 30S is to prevent negative pressure 
from pulling the vessel wall into the cannula and to reduce the 
risk of damage to the vena cava. The blood pump 310 serves 
30 as an artificial heart that drives the blood simultaneously 
through the entire combined ECMO-CVVH system 300. The 
blood is carried through the oxygenator 31S, which serves as 
an artificial lung that oxygenates the blood and removes car-
bon dioxide. Once the blood has been oxygenated, pump 310 
35 causes the oxygenated blood to be carried into the patient. The 
flow probe 32S is used to physically test the amount of fluid 
that is running in the circuit. The output of the flow probe 32S 
is a number representative of the amount of fluid running in 
40 
the circuit, measured in liters per hour. 
As illustrated in FIG. 3A, the CVVH device 320 is inserted 
between the blood pump 310 and the oxygenator 31S. The 
blood pump 310 drives the deoxygenated blood through the 
CVVH device 320. The novel CVVH device 320, described 
in greater detail below in connection with FIGS. 4A-9B, is 
45 configured to directly measure the volume of fluid removed 
from a patient during therapy and utilize that measurement in 
order to determine a more accurate amount of replacement 
fluid that is to be returned to the patient. This aspect of the 
present invention may be utilized in a stand alone CVVH 
50 device or within the CVVH portion of the combined ECMO-
CVVH system 300. There is a direct correlation between the 
amount of volume that is extracted from a patient in ultra 
filtrate that is created during therapy and the amount that 
optimally should be returned to the patient as replacement 
55 fluid. The novel aspect of the CVVH portion of the present 
invention facilitates optimal return of replacement fluid. After 
the blood has been processed in the CVVH device 320, it is 
carried back to the ECMO bladder 30S. The blood is then 
FIG. 6 is a drawing of a dual syringe-pump system with a 
pair of pistons coupled to a translating arm that may be used 60 
in an embodiment of the present invention; 
circulated back through the ECMO system to the patient. 
Prior to the filtered blood entering the patient, the flow probe 
32S measures the actual post-membrane flow for calculation 
FIG. 7 is a drawing of a singular syringe-pump system with 
a single piston that may be used in an embodiment of the 
present invention; 
FIGS. SA and SB are drawings showing the mechanisms 
involved in the production of a perfect fluid balance according 
to the present invention; and 
of the hemofilter runoff. 
FIG. 3B illustrates an alternative embodiment of the 
present invention, a combined ECMO-CVVH system 300 
65 comprised of an ECMO bladder 30S, an ECMO blood pump 
310, an oxygenator 31S, a flow probe 32S, a novel CVVH 
device 320, a CVVH blood pump 33S, and a post bladder 
US 8,206,594 B2 
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blood access port 340. Blood is continuously drained from a 
patient's venous system and circulated through the ECMO 
bladder 305. The ECMO blood pump 310 draws blood from 
the ECMO bladder 305, which works like the right atrium. 
The function of this ECMO bladder 305 is to prevent negative 5 
pressure from pulling the vessel wall into the cannula and to 
reduce the risk of damage to the vena cava. The ECMO blood 
pump 310 serves as an artificial heart that drives the blood 
through the ECMO circuit 300 and back to the patient. The 
blood is carried through the oxygenator 315, which serves as 10 
an artificial lung that oxygenates the blood and removes car-
bon dioxide. Once the blood has been oxygenated, the ECMO 
blood pump 310 causes the oxygenated blood to be carried 
into the patient. 
As illustrated in FIG. 3B, in this embodiment, the CVVH 15 
device 320 is inserted between the ECMO blood pump 310 
and the ECMO bladder 305. In this configuration a CVVH 
blood pump 335 drives deoxygenated blood from the ECMO 
bladder 305 through the CVVH device 320 rather than relying 
8 
long as they perform the function of facilitating a negative 
fluid balance within the system. 
There are two consecutive steps involved in the operation 
of this aspect of the CVVH system illustrated. Switching 
between the first and second steps is controlled by a system of 
valves, which allow or block communication between the 
various components of the fluid management system. Valves 
450, 455, 460, 465, 470, and 475 are used to control the flow 
of filtered blood and replacement fluid in the system. Valve 
450 is positioned between the fluid replacement bag 411 and 
the replacement fluid chamber 420. Valve 455 is positioned 
between the replacement fluid chamber 420 and the filtered 
blood. Valve 460 is positioned between the hemofilter 416 
and the ultrafiltrate fluid chamber 425. Valve 465 is posi-
tioned between the ultrafiltrate fluid chamber 425 and the 
drainage bag 445. Valve 470 is positioned downstream 
between the filtered blood and the syringe 431 and valve 475 
is positioned between the negative balance bag 435 and the 
syringe 431. 
Referring now to FIG. 4A, in the first step, the linear piston 
400 moves up within the cylinder 405. Accordingly, valve 460 
is open and valve 465 is closed, thereby allowing ultrafiltrate 
415 to enter and fill the ultrafiltrate fluid chamber 425. Con-
on the ECMO blood pump 310 to drive the blood. The novel 20 
CVVH device 320 will be described in greater detail below in 
connection with FIGS. 4A-9B. After the blood has been pro-
cessed in the CVVH device 320, it is carried back to post 
bladder blood access port 340. The blood then continues 
through the ECMO system to the patient. Prior to the filtered 
blood entering the patient, the flow probe 325 measures the 
actual post-membrane flow for calculation of the hemofilter 
runoff. 
currently, valve 450 is closed and valve 455 is open, thereby 
25 allowing replacement fluid 410 to exit the replacement fluid 
chamber 420. 
Referring to FIGS. 4A and 4B, aspects of CVVH system 
400 illustrating the principles of"conservation of volume" in 30 
fluid management as applied in the present invention are 
shown. As, illustrated, a unique linear positioner 402 is 
employed as shown in FIGS. 4A and4B. The linearpositioner 
402 translates within a cylinder 405 and simultaneously con-
trols both the delivery of replacement fluid 410 from a 35 
replacement fluid bag 411 and the removal ofultrafiltrate 415 
after the blood has been filtered by a hemofilter 416. The 
linear positioner 402 divides the cylinder 405 into two cham-
bers, namely replacement fluid chamber 420 and ultrafiltrate 
fluid chamber 425. The replacement fluid chamber 420 is 40 
dedicated to the delivery of replacement fluid 410 and the 
ultrafiltrate fluid chamber 425 is dedicated to the drainage of 
ultrafiltrate 415. The linear positioner 402, which is commer-
cially available, facilitates balanced removal of ultrafiltrate 
and delivery of replacement fluids. In the present embodi- 45 
ment, linear positioner 402, model number LP28-T0150-
D01-G21-M1322-H3-L2, is manufactured by Parker Hanni-
In this first step, the same volumes ofultrafiltrate 415 and 
replacement fluid 410 are extracted and delivered, respec-
tively. In the event that it is determined that a patient has fluid 
overload, the system may be configured to generate a net 
negative fluid balance in order to correct the fluid overload. A 
net negative fluid balance is achieved using the syringe pump 
system 430 located downstream of the replacement fluid 
chamber 420. In this case, valve 470 is open and valve 475 is 
closed, thereby allowing a portion of the replacement fluid to 
be captured in the syringe 431 of the syringe-pump system 
430. Hence, the captured portion of replacement fluid will not 
enter the ECMO bladder. For example, during operation, if 
500 ml of ultrafiltrate 415 is removed from the patient, the 
system automatically pulls up 500 ml of replacement fluid 
from the replacement fluid bag 411. If the 500 ml ofreplace-
ment fluid is pushed back into the patient, there would be an 
even balance. To create a negative balance, downstream of the 
pump, valve 470 is opened so that replacement fluid 410 may 
be extracted and placed in the negative fluid balance bag 435. 
In this example, the amount of replacement fluid that is deliv-
ered back to the ECMO bladder is less than 500 ml. 
It is also contemplated that the present invention shall 
include a processor, and a software module that operatively 
controls the motion of the syringe pump system 430 and the 
linear positioner 402. The linear positioner 402 controls the 
replacement fluid piston-syringe and the ultrafiltration pis-
ton-syringe and thereby controls the rate of fluid replacement 
and extraction with respect to each other. When it is necessary 
fin Corporation of Cleveland Ohio. It is contemplated that 
other linear positioners may be utilized so long as they per-
form the function of operating both the replacement fluid and 50 
ultrafiltration piston-syringes. The pinch valves utilized in the 
present embodiment are also commercially available, model 
number 100P3-MP12-05-S-F, manufactured by Bio Chem 
Valve Inc, of Boonton, N.J. It is contemplated that other pinch 
valves or valve systems may be used. 
A syringe-pump system 430 consisting of a syringe 431 
and piston 432, a negative fluid balance bag 435, and valves 
470 and 475 are located downstream of the replacement fluid 
chamber 420. The syringe-pump system 430 removes some 
replacement fluid 410 before its delivery to an ECMO bladder 60 
in order to achieve a net negative fluid balance. When the 
syringe 431 is full, its contents are emptied into the negative 
fluid balance bag 435. The syringe pump system 430 utilized 
55 to create the negative fluid balance, the syringe pump system 
430 is automatically engaged by the processor and software 
controls to facilitate an appropriate level of replacement fluid 
removal from the circuit. The processor and software module 
in the present embodiment of the invention is commercially 
available, model 309653, manufactured by Becton Dickinson 65 
of Franklin Lakes, N.J. It is contemplated that syringes other 
than the specific model identified herein may be utilized, so 
shall be completely integrated and are operatively connected 
to a user interface that allows a system user to input data 
representative of the rate at which fluid is to be replaced and 
the rate at which fluid is to be extracted from a patient. 
Now turning to FIG. 4B, in the second step, the linear 
piston 400 moves down within the cylinder 405. Accordingly, 
valve 460 is closed and valve 465 is open, thereby allowing 
ultrafiltrate 415 to drain from the ultrafiltrate fluid chamber 
425 into the drain bag 445. Concurrently, valve 450 is open 
US 8,206,594 B2 
9 
and valve 4SS is closed, thereby allowing replacement fluid 
410 from the replacement fluid bag 411 to enter and fill the 
replacement fluid chamber 420. If the syringe pump system 
430 was used to produce a net negative fluid balance as 
described in the first step in connection with FIG. 4A, then the 5 
syringe 431 that contains replacement fluid drains into the 
negative balance bag 43S and the contents of the negative 
balance bag 43S are emptied. To allow this process to occur, 
valve 470 is closed and valve 47S is open. 
One embodiment of the present invention as described 10 
above in FIGS. 4A and 4B is illustrated herein in connection 
with FIGS. SA and SB. In an effort to present a compact 
design, the mechanical implementation of the above-de-
scribed principles is modified such that a dual syringe-pump 
15 
system that includes a pair of pistons coupled to a translating 
arm is used to create two separate chambers instead of the 
linear piston 400 illustrated in FIGS. 4A and 4B. This aspect 
10 
per minute and thereby the maximum flow rate may be modi-
fied by altering the dimensions of the linear positioner 610. 
Now turning back to FIG. SA, the negative fluid balance 
pump compartment SlS houses a singular syringe-pump sys-
tem S64 having a negative fluid balance syringe S6S and a 
negative fluid balance piston S7 S. This singular syringe-pump 
system S64 extracts a portion of the replacement fluid in order 
to achieve a net negative fluid balance. The singular syringe-
pump system S64 is mounted in-line with the dual syringe-
pump system SSO. The system S64 extracts replacement fluid 
before this fluid is delivered to the patient, thus reducing the 
overall replacement fluid flow rate while maintaining the 
same ultrafiltrate removal flow rate. 
Briefly turning to FIG. 7, the singular syringe-pump sys-
tem S64 used in the present invention is shown. As mentioned 
previously, the system S64 has a negative fluid balance 
syringe S6S and a negative fluid balance piston S7S. Similar to 
the dual piston-syringe system SSO of FIG. 6, this singular of the present invention is described in greater detail herein 
below. 
Referring now to FIGS. SA and SB, the front and back 
views, respectively, of a novel CVVH device are shown. The 
CVVH device 320 has a front panel SOO as shown in FIG. SA 
and a back panel SOS as shown in FIG. SB. 
20 piston-syringe system S64 is driven by a linear positioner 710 
that consists of an identical lead screw (not shown) and step-
per motor (not shown) programmed via a stepper drive S20 
(FIG. SA) mounted on the front panel SOO. Specifically, the 
In FIG. SA, the front panel SOO includes a perfect fluid 25 
balance pump compartment SlO, a negative fluid balance 
pump compartment SlS, a stepper drive S20, a hemofilter 
S2S, a replacement fluid bag S30 and a negative fluid balance 
bag S3S. An inlet S40 is connected to the membrane oxygen-
ator 31S of the ECMO system of FIG. 3 while an outlet S4S is 30 
connected to the ECMO bladder 30S of FIG. 3. The CVVH 
stepper drive S20 controls the motion of both piston-syringe 
systems SSO and S64. 
Referring back to FIG. SA, the compartments SlO and SlS 
can be enclosed in a transparent box with a hinged lid made of 
polycarbonate in order to allow for easy access. In FIG. SA, 
space is provided above the compartments SlO and SlS for 
the replacement fluid bag S30 and the negative fluid balance 
bag S3S. These bags S30 and S3S can be placed in individual 
compartments as shown in FIG. SA, whereby the compart-
ments for the bags have a transparent box containing a sliding 
device 320 can be mounted on a stand S80 with wheels for 
mobility. Stepper drive S20 is commercially available, manu-
factured by Parker Hannifin, model number VIX-250. It is 
contemplated that stepper drives other than the specific model 
identified herein may be utilized, so long as it performs the 
function of controlling the motion of the linear positioner. 
35 
drawer that accommodates a 1000 mL disposable bag (Vi-
aflex bag, Baxter International Inc., Deerfield, Ill.). The 
present invention was designed as described herein to sim-
plify the handling of the fluids and to ensure fluid sterility, as Referring still to FIG. SA, the perfect fluid balance pump 
compartment SlO houses a dual syringe-pump system SSO, 
which includes a replacement fluid syringe SSS, replacement 40 
fluid piston SS6, a toxin clearance or ultrafiltration syringe 
S60, and toxin clearance or ultrafiltration piston S61. The 
pistons SS6 and S61 are coupled to a translating arm 60S, as 
shown in FIG. 6, which is a detailed illustration of the dual 
syringe-pump system SSO. This syringe-pump system SSO is 
used to achieve a perfect fluid balance. 
well as the sterility of the whole system. 
Before the CVVH or fluid management device 320 can 
function properly, a replacement fluid bag S30 filled with 
replacement fluid is positioned in the CVVH device 320 and 
an empty negative fluid bag S3S is positioned in the CVVH 
device 320. In addition, before the combined ECMO-CVVH 
45 system is connected to the patient, the replacement fluid 
syringe SSS is filled with replacement fluid while the ultrafil-
tration or toxin clearance syringe S60 is mounted with its 
piston S61 pushed to its lowest position (i.e., minimum stroke 
Turning briefly to FIG. 6, the dual syringe-pump system 
SSO incorporated in the present invention consists of a pair of 
pistons SS6 and S61 coupled to a single translating arm 60S. 
The pistons SS6 and S61 push or pull fluid in their respective 50 
syringes SSS and S60 (60 cc syringe model 309653, BD, 
Franklin Lakes, N.J.). Syringe SSS delivers replacement fluid 
while syringe S60 extracts the ultrafiltrate. 
position). 
In FIG. SA, the hemofilter S2S can be mounted vertically 
on the left side of the replacement fluid bag S30. Other com-
ponents of the front panel SOO include tubing (high-purity 
medical grade silicone tubing, part #51845K55, McMaster-
Carr, Aurora, Ohio) for connecting the syringes and fluid bags This dual syringe-pump system SSO achieves a perfect fluid 
balance as the displacement of the translating arm 60S is 
identical for each piston while maintaining sterility as the 
replacement fluid and ultrafiltrate are stored in their respec-
tive syringes SSS and S60. The translating arm 60S is attached 
to a bearing truck (not shown) driven by a linear positioner 
610 (LP28T0150-D01-G21-M1322-H3-L2, Parker Hannifin 
Corp., Cleveland, Ohio). The linearpositioner 610 consists of 
a lead screw (not shown) and a stepper motor (not shown) 
programmed via a stepper drive S20 (FIG. SA) mounted on 
the front panel SOO. The linear positioner 610 utilized in the 
embodiment illustrated is dimensioned to achieve up to four 
strokes per minute, resulting in a maximum flow rate of 8 
L/hour. It is contemplated that maximum allowable strokes 
55 to the stepper driver and three three-way pinch valves S8S, 
S87, and S89 (100P3-MP12-05-S-F, Bio-Chem Valve Inc., 
Boonton, N.J.) for controlling the path of each fluid from the 
syringes SSS, S60, and S6S to the tubing network. The pinch 
valves chosen are designed such that there is no contact 
60 between the valve components and the fluid, thereby facili-
tating system sterility. 
In FIG. SA, pinch valve S8S connects the replacement fluid 
syringe SSS to either the hemofilter outlet or the replacement 
fluid bag S30. Pinch valve S87 connects the ultrafiltration or 
65 toxin clearance syringe S60 and either the ultrafiltrate port of 
the hemofilter or the ultrafiltrate clearance bag S90 shown in 
FIG. SB. Pinch valve S89 connects the negative fluid balance 
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syringe S6S to either the tube connecting the replacement 
fluid syringe SSS to the hemofilter outlet or the negative fluid 
balance bag S3S. 
12 
are all that is necessary to achieve that result. Once the two-
phase cycle has ended, the system reinitializes to restart phase 
one. 
When the novel CVVH device is operated to produce a net 
negative fluid balance, two additional phases occur involving 
the singular syringe-pump system. FIGS. 9A and 9B are 
drawings showing the mechanisms involved in the production 
of a negative fluid balance according to the present invention. 
In FIG. 9A, the first phase occurs at the same time as the first 
Now referring to FIG. SB, the back panel SOS is designed to 
house the ultrafiltrate clearance bag S90. For ease and sim- 5 
plicity, the ultrafiltrate clearance bag S90 can be housed in a 
compartment having a drawer for the bag S90. In this 
example, a 5000 mL disposable bag can be used for the 
collection ofultrafiltrate that is removed from the hemofilter 
S2S of FIG. SA. 10 
phase in the production of a perfect fluid balance of FIG. SA. 
In this phase, extra replacement fluid is removed and involves 
a third pinch valve 900 that connects the replacement fluid 
coming from the replacement fluid syringe SlO to the nega-
tive fluid balance syringe 90S. While replacement fluid is 
delivered to the filtered blood by the replacement fluid 
There are two modes of operation in accordance with the 
present invention, namely the production of perfect fluid bal-
ance and the production of net negative fluid balance. The first 
mode involves the dual syringe-pump system and the second 
mode involves the singular syringe-pump system. 
Now turning to FIGS. SA and SB, drawings showing the 
mechanisms involved in the production of a perfect fluid 
balance according to the present invention are illustrated. A 
perfect fluid balance is attained in two phases. FIG. SA rep-
resents the first phase. In FIG. SA, the first phase in the 
production of a perfect fluid balance consists of the delivery 
of replacement fluid and the extraction of ultrafiltrate. Two 
pinch valves SOO and SOS are involved in performing these 
functions. The first pinch valve SOO connects the replacement 
fluid syringe SlO to the filtered blood coming from the hemo-
filter SlS. The second pinch valve SOS connects the ultrafil-
trate coming from the hemofilter SlS to the ultrafiltration or 
toxin clearance syringe S20. During the first phase, while 
replacement fluid is delivered by the replacement fluid 
syringe Sl 0 and is mixed with the blood filtered by the hemo-
filter SlS, ultrafiltrate is extracted from the hemofilter SlS and 
is stored in the toxin clearance syringe S20. When the pistons 
S2S and S30 reach their maximum stroke, specifically when 
the replacement fluid syringe Sl 0 is full and the ultrafiltration 
syringe S20 is empty, sensors mounted on the linear posi-
tioner relay this information to the pinch valves SOO and SOS. 
In response to receiving this information, the pinch valves 
SOO and SOS switch to their opposite state and the linear 
positioner drives the pistons S2S and S30 in their opposite 
direction. 
The sensors, mounted on the linear positioner, are utilized 
to transmit information reflecting the location of the linear 
positioner along the rail. There are at least two sensors, which, 
in the present embodiment indicate whether the linear posi-
tioner is at the beginning or at the end of the rail. These 
sensors interface with the pinch valves in the system. The 
sensors are used to switch the pinch valves to different con-
figurations. Each time the linear positioner reaches the end of 
the rail, the pinch valves are switched to their opposite state. 
If a first pinch valve is open, the second pinch valve is closed 
and if the second pinch valve is open the first pinch valve is 
closed. 
FIG. SB represents the second phase. In FIG. SB, the sec-
ond phase in the production of a perfect fluid balance consists 
of refilling the replacement fluid syringe Sl 0 and draining the 
ultrafiltration syringe S20. The first pinch valve SOO now 
connects the replacement fluid bag S40 to the replacement 
fluid syringe Sl 0 and the second pinch valve SOS connects the 
ultrafiltration syringe S20 to the ultrafiltrate clearance bag 
located on the back panel (not shown) of the CVVH device. 
Under the action of the translating arm, the empty replace-
ment fluid syringe Sl 0 refills with replacement fluid while the 
full ultrafiltration syringe S20 empties its toxin content into 
the ultrafiltrate clearance bag located on the back panel (not 
shown) of the CVVH device. When the novel CVVH device 
is operated to achieve a perfect fluid balance, these two phases 
15 syringe SlO, some of the replacement fluid is captured by the 
negative fluid balance syringe 90S before this fluid gets 
injected into the filtered blood. The relative flow rates 
achieved by the replacement fluid syringe and the negative 
balance syringe determine the overall flow rate of fluid 
20 removal from the patient. When the negative fluid balance 
syringe 90S is full, the third pinch valve 900 switches to its 
opposite state and the piston 910 translates in the opposite 
direction as shown in FIG. 9B. 
FIG. 9B represents the second phase. In FIG. 9B, the third 
25 pinch valve 900 allows communication between the negative 
fluid balance syringe 90S and the negative fluid balance bag 
91S. Once the negative fluid balance syringe 90S is full, the 
syringe 90S empties its contents into the negative fluid bal-
ance bag 91S. As the piston 910 reaches its minimum stroke, 
30 pinch valve 900 switches back to its initial state and the cycle 
is repeated. 
Referring now to FIG. 10, the present invention is a CVVH 
system 336 for use in patients that are not receiving ECMO. 
The CVVH circuit utilizes the same components as previ-
35 ously described in FIG. 3B; however the method ofobtaining 
venous blood from the patient differs. Since the patient is not 
on ECMO, central venous access must be obtained with the 
use of a multiple lumen large bore intravenous dialysis cath-
eter (not shown) 336. Many standard dialysis catheters are 
40 commercially available (for example, the Mahurkar 
series -Model #539001 SF, 9 cm dual lumen dialysis cath-
eter, Model #101001 12F, 13 cm triple lumen dialysis cath-
eter, and Model #102003 12F, 20 cm triple lumen dialysis 
catheter, Tyco Healthcare, Mansfield Mass.) and the choice of 
45 catheter should be appropriate to the patient's size, expected 
duration of renal replacement therapy, and specific medical 
condition. 
As illustrated in FIG. 10, the CVVH system 304 is com-
prised of a patient with a standard dialysis access catheter 
50 1010, a CVVH blood pump 33S, and the novel CVVH device 
320. Using the CVVH blood pump 33S, blood is continuously 
drained from a patient's venous system through the venous 
lumen of the dialysis catheter 336. The force generated by the 
CVVH blood pump 33S is utilized to circulate the blood 
55 through the novel CVVH device 320. In this configuration the 
novel CVVH device 3 20 is inserted in the venous lumen of the 
dialysis catheter 336 after the CVVH blood pump 33S. Once 
the blood has been treated with CVVH device 320, it is 
returned into the arterial lumen of the dialysis catheter 336. 
60 The force generated by the CVVH blood pump 33S as well as 
the dual syringe pump system SSO subsequently returns the 
blood to the patient via the arterial lumen of the dialysis 
access catheter 336. 
Reference may be made throughout this specification to 
65 "one embodiment," "an embodiment," "embodiments," "an 
aspect," or "aspects" meaning that a particular described fea-
ture, structure, or characteristic may be included in at least 
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one embodiment of the present invention. Thus, usage of such 
phrases may refer to more than just one embodiment or 
aspect. In addition, the described features, structures, or char-
acteristics may be combined in any suitable manner in one or 
more embodiments or aspects. Furthermore, reference to a 
single item may mean a single item or a plurality of items,just 
as reference to a plurality of items may mean a single item. 
Moreover, use of the term "and" when incorporated into a list 
is intended to imply that all the elements of the list, a single 
item of the list, or any combination ofitems in the list has been 10 
contemplated. 
One skilled in the relevant art may recognize, however, that 
the invention may be practiced without one or more of the 
specific details, or with other methods, resources, materials, 
etc. In other instances, well known structures, resources, or 15 
operations have not been shown or described in detail merely 
to avoid obscuring aspects of the invention. 
While example embodiments and applications of the 
present invention have been illustrated and described, it is to 
be understood that the invention is not limited to the precise 20 
configuration and resources described above. Various modi-
fications, changes, and variations apparent to those skilled in 
the art may be made in the arrangement, operation, and details 
of the methods and systems of the present invention disclosed 
herein without departing from the scope of the claimed inven- 25 
ti on. 
The above specification, examples and data provide a 
description of the manufacture and use of the invention. Since 
many embodiments of the invention can be made without 
departing from the spirit and scope of the invention, the 30 
invention resides in the claims hereinafter appended. 
We claim: 
1. A method for managing fluid for accurate continuous 
venovenous hemofiltration, comprising the steps of: 
(a) filling a first container with replacement fluid; 
(b) continuously filtering unfiltered blood to extract ultra-
filtrate, thereby producing filtered blood; 
35 
14 
fluid transferred to the third container is not combined 
with the filtered blood, thereby producing a negative 
fluid balance between the ultrafiltrate extracted from the 
filtered blood and the replacement fluid transferred to 
the filtered blood; and 
(j) occurring simultaneously with the performance of the 
step (g), emptying the portion of the replacement fluid 
that is in the third container so that the third container no 
longer contains the replacement fluid. 
4. The method of claim 3, further comprising the step of 
continuously repeating the steps (b) through (j). 
5. The method of claim 1, further comprising the steps of: 
(i) continuously monitoring a patient to determine a need 
for a zero fluid balance and a negative fluid balance; 
(j) in the event that it is determined that the zero fluid 
balance is necessary, upon detecting that the second 
container no longer contains the ultrafiltrate, continu-
ously repeating the steps (b) through (h) for producing 
the zero fluid balance between the ultrafiltrate extracted 
from the filtered blood and the replacement fluid trans-
ferred to the filtered blood; and 
(k) in the event that it is determined that the negative fluid 
balance is necessary, 
(1) occurring simultaneously with the performance of 
the step ( c ), transferring a portion of the replacement 
fluid to a third container so that the portion of the 
replacement fluid transferred to the third container is 
not combined with the filtered blood, thereby produc-
ing the negative fluid balance between the ultrafiltrate 
extracted from the filtered blood and the replacement 
fluid transferred to the filtered blood; 
(2) occurring simultaneously with the performance of 
the step (g), emptying the portion of the replacement 
fluid that is in the third container so that the third 
container no longer contains the replacement fluid; 
and 
(3) continuously repeating the steps (b) through (h) and 
(k). (c) transferring the replacement fluid from the first con-
tainer to the filtered blood, thereby combining the 
replacement fluid with the filtered blood; 
6. A method for managing fluid for accurate continuous 
40 venovenous hemofiltration, comprising the steps of: 
( d) occurring simultaneously with the performance of step 
( c ), transferring the ultrafiltrate to a second container in 
an amount equal to an amount of replacement fluid 
transferred from the first container; 
( e) continuously monitoring a state of the replacement fluid 45 
in the first container and a state of the ultrafiltrate in the 
second container; 
( f) upon detecting that the first container no longer contains 
the replacement fluid, stopping the transfer of the ultra-
filtrate to the second container; 
(g) after transferring all of the replacement fluid from the 
first container, refilling the first container with additional 
replacement fluid; and 
50 
(h) occurring simultaneously with the performance of step 
(g), emptying the ultrafiltrate that is in the second con- 55 
tainer so that the second container no longer contains the 
ultrafiltrate. 
2. The method of claim 1, further comprising the step of: 
upon detecting that the second container no longer contains 
the ultrafiltrate, continuously repeating the steps (b) 60 
through (h) for producing zero fluid balance between the 
ultrafiltrate extracted from the filtered blood and the 
replacement fluid transferred to the filtered blood. 
3. The method of claim 1, further comprising the steps of: 
(i) occurring simultaneously with the performance of the 65 
step ( c ), transferring a portion of the replacement fluid to 
a third container so that the portion of the replacement 
(a) providing a specific amount of replacement fluid in a 
container; 
(b) providing a replacement fluid piston-syringe that is 
initially filled with the replacement fluid, whereas a 
piston of the replacement fluid piston-syringe is in a 
maximum stroke position; 
(c) providing an ultrafiltration piston-syringe that is ini-
tially empty, whereas a piston of the ultrafiltration pis-
ton-syringe is in a minimum stroke position; 
( d) coupling the replacement fluid piston-syringe and the 
ultrafiltration piston-syringe using a linear positioner 
having sensors capable of detecting relative positions of 
the pistons of the replacement fluid piston-syringe and 
the ultrafiltration piston-syringe; 
( e) employing a first pinch valve directly connecting the 
replacement fluid piston-syringe to blood filtered by a 
hemofilter; 
(f) employing a second pinch valve directly connecting 
ultrafiltrate filtered out by the hemofilter to the ultrafil-
tration piston-syringe; 
(g) delivering the replacement fluid in the replacement 
fluid piston-syringe to the blood filtered by the hemofil-
ter; 
(h) occurring simultaneously with the performance of the 
step (g), extracting the ultrafiltrate from the hemofilter 
using the ultrafiltration piston-syringe and storing the 
ultrafiltrate in the ultrafiltration piston-syringe; 
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(i) relaying information from the sensors to the first and 
second pinch valves regarding the relative positions of 
the pistons of the replacement fluid piston-syringe and 
the ultrafiltration piston-syringe; and 
G) upon occurrence of both pistons independently reaching 
either a minimum or maximum stroke position, causing 
the first and second pinch valves to switch to an opposite 
state and simultaneously causing the pistons of the 
replacement fluid piston-syringe and the ultrafiltration 
piston-syringe to change directions; 10 
(k) upon the first and second pinch valves switching to the 
opposite state, causing the first pinch valve to directly 
connect the container containing the replacement fluid 
to the replacement fluid piston-syringe for refilling the 
replacement fluid piston-syringe with the replacement 15 
fluid and simultaneously causing the second pinch valve 
to directly connect the ultrafiltrate piston-syringe to a 
container for emptying the ultrafiltrate from the ultrafil-
trate piston-syringe; and 
(I) simultaneously refilling the replacement fluid piston- 20 
syringe with the replacement fluid and emptying the 
ultrafiltrate from the ultrafiltrate piston-syringe. 
7. The method of claim 6, further comprising the step of 
continuously repeating the steps (g) through (I) for providing 
zero fluid balance. 25 
8. The method of claim 6, further comprising the steps of: 
(m) employing a third pinch valve directly connecting the 
replacement fluid flowing from the replacement fluid 
piston-syringe to a negative fluid balance piston-sy-
ringe; 30 
(n) removing a portion of the replacement fluid from the 
replacement fluid piston-syringe and storing the 
removed portion of the replacement fluid in the negative 
fluid balance piston-syringe so that removed portion of 
replacement fluid does not enter the filtered blood, 35 
thereby producing a negative fluid balance; and 
( o) occurring simultaneously with the performance of the 
step (!), emptying the removed portion of the replace-
ment fluid from the negative fluid balance piston-sy-
ringe. 40 
9. The method of claim 8, further comprising the step of 
continuously repeating the steps (g) through ( o ). 
10. A system for managing fluid for accurate continuous 
venovenous hemofiltration, comprising: 
(a) a hemofilter configured to continuously filter unfiltered 45 
blood to extract ultrafiltrate, thereby producing filtered 
blood; 
(b) a first container configured to be filled with replacement 
fluid; 
( c) a second container and the first container coupled to a 50 
translating arm, wherein the translating arm is config-
ured to move to simultaneously allow the replacement 
fluid to be transferred from the first container to the 
filtered blood and allow the ultrafiltrate to be transferred 
from the hemofilter to the second container, the amount 55 
of the replacement fluid and the ultrafiltrate transferred 
being equal to each other; and 
( d) at least one sensor being structurally connected to the 
translating arm, the sensor being configured to continu-
ously monitor a relative position of the translating arm, 60 
thereby determining whether there is the replacement 
fluid contained in the first container and the ultrafiltrate 
contained in the second container. 
11. The system of claim 10, further comprising: 
a third container configured to contain a portion of the 65 
replacement fluid that is being transferred from the first 
container to the filtered blood so that the portion of 
16 
replacement fluid transferred to the third container is not 
combined with the filtered blood, thereby producing a 
negative fluid balance between the ultrafiltrate extracted 
from the filtered blood and the replacement fluid trans-
ferred to the filtered blood. 
12. A system for managing fluid for accurate continuous 
venovenous hemofiltration (CVVH) in extracorporeal mem-
brane oxygenation, comprising: 
a container configured to contain replacement fluid; 
a replacement fluid piston-syringe configured to be filled 
with the replacement fluid, the replacement fluid piston-
syringe including a piston; 
an ultrafiltration piston-syringe being configured to be 
filled with ultrafiltrate, the ultrafiltration piston-syringe 
including a piston; 
the replacement fluid piston-syringe and the ultrafiltration 
piston-syringe being coupled to a translating arm having 
at least one sensor capable of detecting relative positions 
of the pistons of the replacement fluid piston-syringe 
and the ultrafiltration piston-syringe; 
a first pinch valve; and 
a second pinch valve, the first pinch and the second pinch 
valve being configured to switch between a first state and 
a second state, 
in the first state, the first pinch valve directly connecting the 
replacement fluid piston-syringe to blood filtered by a 
hemofilter, and the second pinch valve directly connect-
ing the ultrafiltrate extracted by the hemofilter to the 
ultrafiltration piston-syringe, 
wherein the sensor is configured to transmit information 
regarding the relative positions of the pistons of the 
replacement fluid piston-syringe and the ultrafiltration 
piston-syringe to the first and second pinch valves; 
wherein, upon the occurrence of both the piston of the 
replacement fluid piston-syringe and the piston of the 
ultrafiltration piston-syringe independently reaching 
either a minimum or maximum stroke position, the first 
and second pinch valves each being configured to switch 
to the second state and the pistons of the replacement 
fluid piston-syringe and the ultrafiltration piston-syringe 
being configured to change directions; and 
wherein upon the first and second pinch valves each 
switching to the second state, the first pinch valve being 
configured to directly connect the container configured 
to contain the replacement fluid to the replacement fluid 
piston-syringe and the replacement fluid piston-syringe 
being configured to be refilled with the replacement fluid 
and the second pinch valve being configured to directly 
connect the ultrafiltrate piston-syringe to a second con-
tainer for the ultrafiltrate and the ultrafiltrate piston-
syringe being configured to empty the ultrafiltrate into 
the second container. 
13. The system of claim 12, further comprising: 
a singular piston-syringe connected to the replacement 
fluid piston-syringe, the singular piston-syringe being 
configured to extract a portion of the replacement fluid 
being delivered to the filtered blood so that the extracted 
portion of replacement fluid is temporarily housed in the 
singular piston-syringe and is not combined with the 
filtered blood, thereby producing a negative fluid bal-
ance between the ultrafiltrate extracted from the filtered 
blood and the replacement fluid transferred to the fil-
tered blood. 
14. The method of claim 1, wherein the step (e) is per-
formed by at least one sensor. 
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15. The method of claim 14, wherein the steps (a) through 
(h) are performed based on a position of one of a translating 
arm or a linear positioner coupled to the first and second 
containers. 
16. The system of claim 10, 
wherein the translating arm is configured to move between 
a minimum and a maximum position, and 
wherein the position of the translating arm corresponds to 
one of afirstphaseora second phase, wherein, in the first 10 
phase, the first container is configured to be refilled with 
additional replacement fluid at a same time as the ultra-
filtrate is emptied from the second container, and 
wherein, in the second phase, the replacement fluid is 
configured to be transferred from the first container at a 
18 
same time as the ultrafiltrate is extracted from the hemo-
filter and transferred to the second container. 
17. The system of claim 16, further comprising: 
a stepper drive configured to move the translating arm 
between the minimum and the maximum position, 
wherein the stepper drive is configured to stop the translat-
ing arm and reverse the direction of the translating arm 
based on the position of the translating arm detected by 
the at least one sensor. 
18. The system of 10, further comprising: 
wherein the translating arm is configured so that a displace-
ment with respect to the first container and the second 
container is identical. 
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